Background-A common single-nucleotide polymorphism (SNP) in the promoter of the Connexin-40 (Cx40) gene GJA5 was suggested to affect Cx40 promoter activity and the risk of atrial fibrillation (AF), but the role of other common Cx40 polymorphisms is unknown. Methods and Results-Eight SNPs within the Cx40 gene region were tested for association with Cx40 levels measured in atrial tissue from 61 individuals. The previously described Cx40 promoter SNP (rs35594137, Ϫ44G3 A) was not associated with Cx40 mRNA levels. However, a common SNP (rs10465885) located in the TATA box of an alternative Cx40 promoter was strongly associated with Cx40 mRNA expression (PϽ0.0001) and displayed strong and consistent allelic expression imbalance in human atrial tissue. A promoter-luciferase assay in cultured murine cardiomyocytes demonstrated reduced activity of the promoter containing the minor allele of this SNP (PϽ0.0001). Both rs35594137 and rs10465885 were tested for association with early-onset lone AF (Յ60 years of age) in 384 cases and 3010 population control subjects. rs10465885 was associated with the AF phenotype (odds ratio, 1.18; Pϭ0.046). This result was confirmed in a meta-analysis including 2 additional early-onset lone AF case-control cohorts (odds ratio, 1.16, Pϭ0.022). rs35594137 was not associated with the lone AF phenotype in any of the cohorts studied or in a combined analysis. Conclusions-A previously described Cx40 promoter SNP was not found to influence Cx40 expression or risk of AF. We describe an alternate promoter polymorphism that directly affects levels of Cx40 mRNA in vivo and is associated with early-onset lone AF. (Circ Arrhythm Electrophysiol. 2011;4:87-93.) The online-only Data Supplement is available at http://circep.ahajournals.org/cgi/content/full/CIRCEP.110.959726/DC1.
C ardiac connexin-40 (Cx40) is found exclusively in the atria and conduction system. Along with connexin-43, it comprises the gap junctions that electrically couple atrial myocytes. 1 As Cx40 is the only connexin found exclusively in the atria, several studies have investigated the effect of genetic alterations in the Cx40 gene gap junction protein, alpha 5 (GJA5) on the development of atrial conduction abnormalities and atrial fibrillation (AF). Complete absence of Cx40 in Cx40 Ϫ/Ϫ mice leads to altered propagation and ectopic rhythms in the atria 2 and arrhythmias on surface ECG. 3 In 15 patients with idiopathic AF, Gollob et al 4 discovered 3 somatic and 1 germ line mutation in the Cx40 coding region, resulting in dominant-negative Cx40 activity.
Clinical Perspective on p 93
The Cx40 gene GJA5 contains 2 alternative first exons (exons 1A and 1B), using separate promoters (promoters A and B), resulting in 2 alternative transcripts (Cx40 transcripts A and B) that share a common second coding exon. 5 In 2003, Groenewegen et al 6, 7 identified a common single nucleotide polymorphism (SNP) in the Cx40 promoter A (rs35594137, Ϫ44G3 A) 6 that was later associated with decreased Cx40 promoter A activity in vitro, atrial vulnerability and AF. 8 We hypothesized that additional common Cx40 polymorphisms may also affect Cx40 expression in human atrial tissues, and that these polymorphisms may predispose to AF.
We characterized a SNP, rs10465885, in the Cx40 promoter B that alters a putative TATA box element and strongly influences expression of Cx40 transcript B and total Cx40 expression in human atria. We further determined that the promoter B SNP acts in cis, influencing expression of the same-strand transcript. The promoter B SNP was significantly associated with early-onset lone AF in a case-control cohort study, and this finding was validated in a meta-analysis including 2 additional cohorts. In contrast to previous reports, we found that the promoter A SNP was not significantly associated with Cx40 expression in vivo, nor was it associated with the AF phenotype.
Methods

Study Subjects
Atrial appendage tissues were obtained from 61 patients undergoing coronary artery bypass grafting, valve surgery, or the Maze surgical AF ablation procedure. Most patients (85.2%) from whom tissues were obtained had a history of AF, and 49.2% of patients had AF at the time of surgery. Supplemental Table 1 (online Data Supplement) provides a detailed description of this cohort.
Three AF case-control cohorts were used to analyze the association of the Cx40 promoter A and B SNPs with the lone AF phenotype. All case subjects had lone AF, defined as AF in the absence of structural heart disease, and all subjects were of European ancestry. In addition, subjects were deemed to have early-onset lone AF if their age at AF diagnosis was Յ60 years.
Subjects from the Cleveland Clinic Lone Atrial Fibrillation GeneBank (CCAF) (nϭ596, with 384 early-onset cases) were used as the discovery cohort along with 3010 population control subjects from the Illumina iControl Database. A replication cohort consisting of AF cases (nϭ119, with 45 early-onset cases) and non-AF control subjects (nϭ7395) was obtained from the Atherosclerosis Risk in Communities (ARIC) study. 9 A second replication case-control cohort consisted of lone AF subjects (nϭ375, with 335 early-onset cases) from the Massachusetts General Hospital Atrial Fibrillation Study (MGH) 10 and non-AF control subjects (nϭ1101) from the Framingham Heart Study (FHS). [11] [12] [13] Supplemental Table 2 provides a detailed description of the 3 cohorts. All subjects gave informed consent, and all studies were approved by their respective institutional review boards.
Other methods are in the online Data Supplement.
Results
Haplotype Analysis of the GJA5 Gene
Seven contiguous SNPs from the Illumina Hap550 BeadChip located within the GJA5 gene and proximal promoter region, plus rs11552588, a component of the previously described Cx40 promoter A haplotype, 6 were studied. Genotypes at these 8 SNPs in the 61 atrial tissue samples were loaded into Haploview v.4.1 (Broad Institute) to calculate their LD relationships ( Figure 1A ). From these data, it was determined that rs12408178 was in perfect LD (r 2 ϭ1) with rs11552588, the SNP at ϩ71 in exon 1A, which is in perfect LD with the promoter A SNP rs35594137 (Ϫ44G3 A). 7, 8 This established rs12408178 as a perfect proxy for the promoter A SNP. In contrast, the promoter A SNP proxies were only moderately linked to the promoter B SNP (r 2 ϭ0.33).
The Promoter B SNP Alters A Putative TATA Box
The sequence of the proximal promoter of human Cx40 transcript B, along with the homologous sequence in other mammalian species, is shown in Figure 1B . The promoter B SNP resides at Ϫ26 bp relative to the start of transcription, where it changes 1 of 2 partially overlapping TATA boxes in the proximal promoter. A summed nucleotide frequency score was calculated for each putative TATA box using the JASPAR 14 nucleotide frequency values of each base position in a 7-base window beginning at the first "T" of each sequence. The summed nucleotide frequency score of the core consensus sequence "TATAAAA" was set to 1.0. Relative to the core consensus sequence, the 3Ј-shifted TATA box sequence had a summed nucleotide frequency score of 0.855. The 5Ј-shifted TATA box sequence score is dependent on the genotype of the promoter B SNP. The "A" allele of this SNP results in a summed nucleotide frequency score of 0.776, whereas the "G" allele results in a poorer score of 0.620.
The Promoter B SNP Genotype Is Associated With Cx40 Transcript Levels In Vivo
cDNAs from 61 human atrial tissue samples were run on Illumina Human Ref-8 v2 expression bead chips, and the signals for total Cx40 and Cx40 transcript A were analyzed. Genotypes at each of the 8 SNPs shown in Figure 1A were tested for an association with Cx40 expression levels. Only the promoter B SNP (rs10465885) genotype was significantly associated with total Cx40 mRNA levels in the 61 atrial tissue samples (Figure 2A , Pϭ0.013, additive genetic model), with the presence of 1 "G" allele at the promoter B SNP genotype associated with a 16% decrease in total Cx40 mRNA expression. As expected, the promoter B SNP was not significantly associated with Cx40 transcript A levels ( Figure 2B , Pϭ0.78, 1-way ANOVA). None of the other 7 SNPs within the Cx40 gene region were significantly associated with total Cx40 mRNA levels (1-way ANOVA, data not shown).
Because none of the probes on the microarray directly measured Cx40 transcript B, quantitative polymerase chain reaction of Cx40 transcript B was performed on cDNA from 31 of the 61 atrial tissue samples. The promoter B SNP genotype was strongly associated with Cx40 transcript B expression in a dose-dependent manner ( Figure 2C , PϽ0.0001, 1-way ANOVA), with the presence of 1 "G" allele associated with 4.3-fold lower levels of Cx40 transcript B. In a linear regression analysis of the additive genetic model, the promoter B SNP genotype was associated with 49% of the variation in Cx40 transcript B expression in the 31 atrial tissue samples, with a corresponding quantitative log of the odds ratio (LOD) score of 4.85.
The Promoter A SNP Does Not Affect Cx40 Levels In Vivo
The genotype at the promoter A SNP proxy was not significantly associated with levels of Cx40 transcript A in the microarray assay of the 61 tissue samples (Figure 3 , Pϭ0.55, additive genetic model). Similarly, quantitative polymerase chain reaction of Cx40 transcript A in the atrial tissue samples failed to show any association of the promoter A SNP proxy with Cx40 transcript A expression (Pϭ0.66, additive genetic model, Supplemental Figure 1 ). In addition, the promoter A SNP proxy was not significantly associated with levels of total Cx40 mRNA (Pϭ0.82, additive genetic model, data not shown).
The Promoter B SNP Acts in Cis to Affect Cx40 Transcript B Expression In Vivo
Because the promoter B SNP alters the sequence of one of an overlapping pair of TATA box elements, we hypothesized that the effect of the promoter B SNP on Cx40 transcript B expression occurs in cis through modulation of transcription. Therefore, we tested for allelic expression imbalance, comparing Cx40 transcript B levels produced from each allele in atrial tissue samples from subjects heterozygous for both the promoter B SNP and an indicator SNP within Cx40 transcript B. In all of these atrial tissue samples, the amount of mRNA produced from the minor G allele at the promoter B SNP was strongly and significantly decreased compared with the amount produced from the major A allele, with a mean decrease of 3.3-fold and a range of 2.2-to 6.3-fold ( Figure  4A ). Representative sequence tracings from both cDNA and gDNA in the region surrounding the indicator SNP rs1043806 are shown in Figure 4C , illustrating the differing allelic ratios. As a control, 1 sample homozygous at the promoter B SNP but heterozygous for an indicator SNP was assayed, and was found to have no significant allelic expression imbalance ( Figure 4A , first bar marked as (Ϫ).
The Promoter A SNP Is Incompletely Associated With Allelic Expression Imbalance
We measured allelic expression imbalance of Cx40 transcript A in atrial tissue samples from subjects heterozygous for the promoter A SNP and the indicator SNP rs11552588 in exon 1 of transcript A. Most samples exhibited small but significant allelic expression imbalance favoring the Ϫ44A allele, with a mean increase in Cx40 transcript A expression of 1.3-fold ( Figure 4B ). However, significant allelic expression imbalance was not observed in 2 samples, and another 2 samples exhibited significant allelic expression imbalance in the opposite direction. This indicates that the promoter A SNP may be in partial LD with a potential causative genetic variant that has a minor effect on the transcription of Cx40 transcript A.
The Promoter B SNP Affects Promoter Activity in Transfected HL-1 Murine Cardiomyocytes
To exclude the influence of other potential genetic variations in LD with the promoter B SNP on Cx40 transcript B expression, we used a promoter-driven reporter gene assay in cultured cells. HL-1 murine atrial cardiomyocytes were transiently transfected with a promoterless firefly luciferase reporter construct (negative control) or constructs driven by the native Cx40 transcript B promoter containing either the A or G allele at the promoter B SNP site. Each transfection included a plasmid expressing ␤-galactosidase as a transfection efficiency control. HL-1 cells transfected with the reporter construct containing the G allele at the promoter B SNP site exhibited 2.4-fold lower luciferase activity compared with cells transfected with the construct containing the A allele ( Figure 5, PϽ0.0001, Student t test) .
The Promoter B SNP Is Significantly Associated With AF
The promoter A SNP proxy (rs12408178) and the promoter B SNP (rs10465885) were tested for association with the early-onset lone AF phenotype (age of diagnosis Ͻ60 years) using 384 CCAF cases and 3010 healthy population control subjects in a logistic regression analysis under a log-additive genetic model. The promoter B SNP was significantly associated with early-onset lone AF status with an odds ratio (OR) of 1.18 (95% confidence interval, 1.00 to 1.39; Pϭ0.046; Figure  6 ), with the underexpressed "G" allele overrepresented in AF cases. In contrast, the promoter A SNP proxy was not significantly associated with early-onset lone AF (ORϭ1.11, Pϭ0.26, Figure 6 ).
Two additional case-control cohorts were used to confirm the findings from the discovery CCAF cohort ( Figure 6 ). The promoter B SNP had an OR of 1.25 for AF in 45 early-onset AF cases and 7300 non-AF control subjects from the ARIC cohort, but because of the small number of cases this was not statistically significant (Pϭ0.31). The promoter A SNP proxy was not significantly associated with early-onset AF in the ARIC cohort (ORϭ1.06, Pϭ0.81). The promoter B SNP had an OR of 1.09 for lone AF in 334 early-onset AF cases from the MGH cohort and 1067 healthy control subjects from the FHS cohort, which was in the same direction as the other 2 studies, but not statistically significant (Pϭ0.42). The promoter A SNP proxy was not significantly associated with early-onset AF in this group (ORϭ0.98, Pϭ0.90). A meta-analysis including all 3 cohorts confirmed the finding of the discovery cohort, revealing a significant association between the promoter B SNP and early-onset lone AF (OR, 1.16; 95% confidence interval, 1.02 to 1.31; Pϭ0.022; Figure 6 ). A similar meta-analysis failed to find a significant association between the promoter A SNP proxy and early-onset lone AF (OR, 1.07; Pϭ0.37; Figure 6 ).
The meta-analyses of the early-onset lone AF case-control studies, including all 3 cohorts, had 80% power to detect a relative risk of 1.16 for the minor allele of the promoter B SNP and a relative risk of 1.18 for the minor allele of the promoter A SNP in the additive genetic model. None of the meta-analyses displayed any significant heterogeneity.
Neither the promoter A nor the promoter B SNP was significantly associated with the lone AF phenotype in any of the cohorts when subjects of all ages were included in their respective AF case cohorts (Supplemental Table 3 ), demonstrating the expected stronger genetic effects in younger cases.
Discussion
We used mRNA expression data and analysis of mRNA allelic expression imbalance in human atrial tissue to characterize a novel regulatory polymorphism in the Cx40 gene GJA5. This polymorphism, rs10465885, is located in the promoter region of Cx40 transcript B, where it alters the configuration of 1 of 2 partially overlapping TATA box elements. The strong correlation between the promoter B SNP and Cx40 mRNA levels and its consistent and profound effect on Cx40 transcript B allelic mRNA expression ratios demonstrate that this polymorphism is strongly associated in cis with transcription of Cx40 transcript B in vivo. Its location in a TATA box element and the results of the promoter-luciferase reporter gene assay provide strong evidence that the promoter B SNP directly affects transcription of Cx40 transcript B.
Comparison of the promoter region altered by the promoter B SNP with a nucleotide frequency matrix of the human TATA box sequence revealed 2 possible overlapping TATA box sequences ( Figure 1B) . The similarity of the 5Ј-shifted TATA box to the consensus TATA sequence is substantially improved by the G3 A transition at the promoter B SNP site. The base affected by the promoter B SNP is not strictly conserved in mammals and, interestingly, the "non-A" allele appears to be present in the sequences of at least 5 other mammalian species. In addition, the chimpanzee genome at this site contains the G allele, suggesting that the A allele could be a gain-of-function mutation unique to humans.
Cx40 Ϫ/Ϫ knockout mice exhibit atrial ectopy and arrhythmias on surface ECG, and rare dominant-negative defects in the Cx40 coding sequence are associated with AF in humans. However, most SNPs associated with complex traits identified by genomewide association studies to date are not located within gene coding regions or open reading frames and are instead expected to affect gene expression. Therefore, we tested for an association between Cx40 promoter polymorphisms and AF.
We found that the newly characterized promoter B SNP was significantly associated with early-onset lone AF in our discovery cohort. Although the association of the promoter B SNP with AF did not reach statistical significance in the 2 individual replication cohorts, these analyses were based on smaller sample sizes and were not adequately powered to detect the effect size observed in the discovery cohort. However, the effect of the promoter B SNP observed in each of the replication cohorts was consistent with the effect observed in the discovery cohort with increased risk associated with the G allele. Thus, a meta-analysis including all 3 cohorts confirmed the significant association between the promoter B SNP and early-onset lone AF. In addition, the G allele resulting in diminished Cx40 expression was overrepresented in the AF cases, suggesting that lower Cx40 levels may also be associated with AF. This is consistent with previous observations 2-4 that have suggested that impaired Cx40 expression or function predisposes to atrial conduction abnormalities and AF. The observed odds ratio of 1.16 per risk allele in the meta-analysis is modest and is expected under natural selection given the high minor allele frequency (0.47) of this SNP. However, the presence of 2 risk alleles is associated with an odds ratio of 1.35, which underscores the potential importance of this SNP in predicting AF risk.
Because each of the 2 replication cohorts did not achieve statistical significance on their own, how strong is the evidence supporting the association of rs10465885 with early-onset lone AF? First, all 3 studies had odds ratios in the same direction, showing increased risk with the underexpressed G allele. Second, the combined meta-analysis with the greatest power was more highly significant than the discovery cohort, demonstrating that as the sample size increased the association grew stronger. Third, other genetic association studies with weak effects (eg, odds ratio of Ϸ1.2) are often not replicated in the individual validation cohorts, but when combined, the effects are highly significant. For example, the recently identified SNP associated with abdominal aortic aneurysm was assessed in 8 separate follow-up cohorts, and 6 of these failed to find a significant association. 15 However, combining these 8 cohorts together yielded a significant association. 15 A prior genome-wide association study meta-analysis for lone AF in subjects 65 years of age or younger detected and validated 2 genome-wide significant loci but did not find a genome-wide significant association for the Cx40 gene. 16 However, many real associations are present that fail to meet the strict standard of genome-wide significance, which is very stringent because of the correction for hundreds of thousands of SNPs tested. For example, genome-wide significant loci for height, which is a highly heritable trait, account for only 5% of the variance in height in studies with tens of thousands of subjects, but 45% of the variance can explained by considering all SNPs simultaneously in a smaller cohort. 17 Thus, many more SNPs add to the heritability of height that cannot be identified with certainty using current statistical methods. We conclude that the evidence on hand supports the association of the Cx40-B promoter SNP rs10465885 with early-onset lone AF, although we cannot definitively rule out that this finding is a false-positive.
Interestingly, the promoter B SNP was not significantly associated with lone AF when subjects of all ages were included in the analyses. The prevalence of conditions that predispose to AF such as hypertension, coronary artery disease, valve disease, and heart failure increases with age. Therefore, although these analyses were performed in subjects with lone AF, the inclusion of older subjects (with AF caused by other "nongenetic" factors) in the AF case cohort may dilute the effect of a potential genetic variant. We confirmed the lack of association of the promoter B SNP with lone AF in subjects of all ages in a recent meta-analysis of 5 case-control cohorts comprising 1335 lone AF cases and 12 844 unaffected subjects, which overlaps the ARIC and MGH/FHS cohorts of the current study. 16 In this study, rs10465885 was not significantly associated with AF (OR, 1.064; 95% confidence interval, 0.93 to 1.22; Pϭ0.64). Age-stratified analysis was not performed in this mega-analysis.
A common SNP in the promoter of Cx40 transcript A, first identified cosegregating with an SCN5A mutation in familial atrial standstill, 6 has also been associated with atrial vulnerability and AF in a small sample of 30 individuals. 8 The association with AF was later replicated in a Taiwanese population of 173 AF patients and 232 control subjects, 7 yielding an odds ratio of 1.54 for the minor allele of the promoter A SNP in the additive genetic model. Promoterluciferase assays in cell culture showed varying (Ͻ20% 7 to 65% 6 ) reduction in the activity of the promoter containing the minor allele of the promoter A SNP. A further study suggested that the minor allele of this promoter SNP negatively affected binding of GATA4, a major cardiac-specific transcription factor, to its binding site in the Cx40 transcript A promoter. 18 We sought to extend these in vitro observations by studying the effect of this SNP on Cx40 mRNA expression levels in vivo in human atrial tissues. However, we were unable to detect a significant effect of the promoter A SNP on Cx40 transcript A or total Cx40 mRNA expression. Similarly, analysis of allelic expression imbalance in individuals heterozygous at the promoter A SNP revealed minimal and inconsistent allelic expression imbalance of Cx40 transcript A. For a candidate polymorphism to be considered a true cis-acting regulatory polymorphism, allelic expression imbalance must be consistent. Thus, our data argues against a true cis-acting regulatory role for the promoter A SNP.
In contrast to previous reports, 7,8 the promoter A SNP was not significantly associated with AF in any of the case-control cohorts, or in the combined meta-analysis. The discordance of our findings with the Taiwanese study could in part be due to race-specific genetic effects or differences in the baseline patient characteristics. However, our meta-analysis had a markedly greater sample size, and was sufficiently powered to detect a relative risk of 1.18 for the minor allele of the promoter A SNP. Our study demonstrated that there was no association between the promoter A SNP and lone AF with an effect size of 1.18 or greater in populations of European ancestry.
In conclusion, we determined that a previously described Cx40 promoter A polymorphism, rs35594137 (Ϫ44G3 A), was not associated with Cx40 mRNA levels, allelic expression imbalance in human atrial tissue, or the lone AF phenotype. However, we identified a different SNP, rs10465885, as a common Cx40 promoter B variant with a direct cis effect on Cx40 gene expression. Importantly, this promoter B SNP was also significantly associated with early-onset lone AF. Additional studies are needed to more fully characterize the effects of this SNP in atrial tissue and its link to AF pathophysiology. However, this study represents an important step toward understanding the genetic determinants of Cx40 expression, as well as the potential role of variation in Cx40 expression as a determinant of AF risk.
